Holen Sie sich die Stockscreener-App
23.95
0.71%
0.17
Handel nachbörslich:
23.60
-0.35
-1.46%
Schlusskurs vom Vortag:
$23.78
Offen:
$23.78
24-Stunden-Volumen:
153.74K
Relative Volume:
1.00
Marktkapitalisierung:
$396.79M
Einnahmen:
$102.48M
Nettoeinkommen (Verlust:
$-191.09M
KGV:
-1.6609
EPS:
-14.4203
Netto-Cashflow:
$-178.93M
1W Leistung:
-0.62%
1M Leistung:
-5.30%
6M Leistung:
+175.10%
1J Leistung:
+341.80%
1-Tages-Spanne:
$23.66
$25.00
1-Wochen-Bereich:
$23.65
$26.34
52-Wochen-Spanne:
$5.231
$26.54
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
23.95 | 393.97M | 102.48M | -191.09M | -178.93M | -14.42 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Institution Moves: What is the Moat Score of Sutro Biopharma IncWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Sutro Biopharma Hits New 52-Week High at $26.54, Up 548.83% - Markets Mojo
[EFFECT] SUTRO BIOPHARMA, INC. SEC Filing - Stock Titan
Market Outlook: Can Sutro Biopharma Inc continue delivering strong returns2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sutro Biopharma enters sales agreement, may offer & sell shares of common stock of up to $100 millionSEC filing - marketscreener.com
Sutro Biopharma Enters Sales Agreement, May Offer & Sell Shares Of Common Stock Of Up To $100 MillionSEC Filing - TradingView
Sutro Biopharma (NASDAQ: STRO) files $100M ATM shelf with TD Cowen - Stock Titan
Gains Report: Why is Sutro Biopharma Inc stock going down2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Earnings Risk: Is now the right time to enter Sutro Biopharma IncWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Value Recap: Is Sutro Biopharma Inc in a bullish channelMarket Sentiment Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Hedge Fund Bets: What is the Moat Score of Sutro Biopharma Inc2026 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Stock Market Recap: Is Sutro Biopharma Inc a potential multi baggerSell Signal & Reliable Intraday Trade Alerts - baoquankhu1.vn
HC Wainwright Lowers Earnings Estimates for Sutro Biopharma - marketbeat.com
Sutro Biopharma (NASDAQ:STRO) Upgraded by Truist Financial to "Strong-Buy" Rating - MarketBeat
Sutro Biopharma Inc buy Deutsche Bank Aktiengesellschaft - sharewise.com
Analyst James Shin Raises Price Target for Sutro Biopharma (STRO) to $55.00 | STRO Stock News - gurufocus.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - MarketBeat
Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating - MarketScreener
HC Wainwright Predicts Sutro Biopharma FY2030 Earnings - MarketBeat
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Pri - gurufocus.com
Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright - MarketBeat
Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8 - MarketScreener
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy By Investing.com - Investing.com Canada
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy - Investing.com
Sutro's FY25 Net Loss Narrows; On Track To Report Initial Phase 1 Data Of STRO-004 In Mid-2026 - RTTNews
Citizens reiterates Sutro Biopharma stock rating on pipeline progress By Investing.com - ca.investing.com
STRO Stock: HC Wainwright & Co. Upgrades Sutro Biopharma | STRO - gurufocus.com
Sutro Biopharma (STRO) Receives Upgrade with Promising Outlook - gurufocus.com
Citizens reiterates Sutro Biopharma stock rating on pipeline progress - Investing.com
Sutro Biopharma Reports 2025 Financial Results, Advances Dual-Payload ADC Pipeline, and Extends Cash Runway to 2028 - Minichart
Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis - Minichart
Sutro Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sutro Biopharma (NASDAQ: STRO) launches $100M ATM program with TD Cowen - Stock Titan
Sutro Biopharma Ends ATM Agreement After 2025 Results - TipRanks
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - Bitget
Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results - marketbeat.com
Sutro Biopharma 2025 10-K: $102.5M revenue, $(22.49) EPS - TradingView
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sutro Biopharma (NASDAQ: STRO) expands ADC pipeline and monetizes partnerships - Stock Titan
Revenue jumps as Sutro Biopharma (NASDAQ: STRO) narrows 2025 loss - Stock Titan
Q4 financial results released by Sutro Biopharma with operational update - Traders Union
BRIEF-Sutro Biopharma FY Revenue USD 102.484 Million Vs. IBES Estimate USD 99.2 Million - TradingView
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
If You Invested $1,000 in Sutro Biopharma (STRO) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Analyst Upgrade: Is now the right time to enter Sutro Biopharma Inc2026 Summary & Community Consensus Trade Alerts - baoquankhu1.vn
Bank Watch: Does H E Equipment Services Inc stock have upside surprise potentialCPI Data & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):